A Review of the Data Supporting Use of COVID-19 Vaccinations in the Pediatric Population

Objective: The objective of this study was to review the effectiveness and safety of COVID-19 vaccinations in the pediatric population. Data Sources: PubMed/Medline (September 2020 to December 2022), the Centers for Disease Control and Prevention, and Food and Drug Administration (FDA) websites. Stu...

Full description

Saved in:
Bibliographic Details
Published in:Annals of Pharmacotherapy 2023-11, Vol.57 (11), p.1328-1340
Main Authors: Stultz, Jeremy S., Eiland, Lea S.
Format: Article
Language:English
Subjects:
Review
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective: The objective of this study was to review the effectiveness and safety of COVID-19 vaccinations in the pediatric population. Data Sources: PubMed/Medline (September 2020 to December 2022), the Centers for Disease Control and Prevention, and Food and Drug Administration (FDA) websites. Study Selection and Data Extraction: Publications regarding the safety and efficacy of COVID-19 vaccinations in children were included. Data Synthesis: Vaccines authorized for use in children include two monovalent mRNA vaccines (≥6 months old) and one monovalent protein subunit adjuvant vaccine (adolescents only). Omicron-specific mRNA bivalent boosters are authorized for children ≥6 months old. Studies after monovalent vaccine authorization illustrated efficacy in children >5 to 6 years of age, specifically decreased severe COVID-19 (including mortality) and multisystem inflammatory response syndrome occurrence (including during Omicron predominance). Available data for children
ISSN:1060-0280
1542-6270
DOI:10.1177/10600280231156625